John M.  Evans net worth and biography

John Evans Biography and Net Worth

John Evans has served as our Chief Executive Officer since January 2018, as our President and Chief Executive Officer from January 2018 through January 2020, and as our interim Chief Executive Officer from April 2017 through January 2018. Mr. Evans previously was a Venture Partner with ARCH Venture Partners. He has also served as a director of Verve Therapeutics, a biotechnology company, since August 2018 and as a director of Prime Medicine, a biotechnology company, since September 2019. Mr. Evans was previously at Agios Pharmaceuticals, a biopharmaceutical company, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. He also helped initiate and lead Agios’ alliance with Celgene Corporation. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company’s pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University. We believe that Mr. Evans is qualified to serve on our Board based on his extensive experience in the pharmaceutical industry and his expansive knowledge of our company based on his role as our Chief Executive Officer. Provided by Tagnifi.

What is John M. Evans' net worth?

The estimated net worth of John M. Evans is at least $26.27 million as of April 1st, 2024. Mr. Evans owns 1,058,343 shares of Beam Therapeutics stock worth more than $26,268,073 as of April 23rd. This net worth approximation does not reflect any other assets that Mr. Evans may own. Additionally, Mr. Evans receives a salary of $1,110,000.00 as CEO at Beam Therapeutics. Learn More about John M. Evans' net worth.

How old is John M. Evans?

Mr. Evans is currently 46 years old. There are 2 older executives and no younger executives at Beam Therapeutics. Learn More on John M. Evans' age.

What is John M. Evans' salary?

As the CEO of Beam Therapeutics Inc., Mr. Evans earns $1,110,000.00 per year. Learn More on John M. Evans' salary.

How do I contact John M. Evans?

The corporate mailing address for Mr. Evans and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected]. Learn More on John M. Evans' contact information.

Has John M. Evans been buying or selling shares of Beam Therapeutics?

During the past quarter, John M. Evans has sold $581,617.26 of Beam Therapeutics stock. Most recently, John M. Evans sold 18,102 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $32.13, for a transaction totalling $581,617.26. Following the completion of the sale, the chief executive officer now directly owns 1,058,343 shares of the company's stock, valued at $34,004,560.59. Learn More on John M. Evans' trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 13 times. They sold a total of 319,468 shares worth more than $9,885,604.19. The most recent insider tranaction occured on April, 1st when insider Amy Simon sold 7,157 shares worth more than $229,954.41. Insiders at Beam Therapeutics own 4.4% of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 4/1/2024.

John M. Evans Insider Trading History at Beam Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Sell18,102$32.13$581,617.261,058,343View SEC Filing Icon  
3/28/2024Sell60,000$33.86$2,031,600.00998,262View SEC Filing Icon  
1/31/2024Sell60,000$25.33$1,519,800.001,058,262View SEC Filing Icon  
4/3/2023Sell5,161$30.31$156,429.911,124,472View SEC Filing Icon  
10/31/2022Sell30,000$46.31$1,389,300.001,058,520View SEC Filing Icon  
7/28/2022Sell30,000$65.75$1,972,500.001,088,520View SEC Filing Icon  
4/28/2022Sell30,000$37.98$1,139,400.001,118,520View SEC Filing Icon  
3/31/2022Sell6,261$59.11$370,087.711,089,070View SEC Filing Icon  
10/6/2021Sell27,700$83.80$2,321,260.00View SEC Filing Icon  
8/19/2021Sell20,000$99.49$1,989,800.00View SEC Filing Icon  
7/7/2021Sell25,000$107.87$2,696,750.001,046,525View SEC Filing Icon  
4/21/2021Sell25,000$70.49$1,762,250.001,038,966View SEC Filing Icon  
See Full Table

John M. Evans Buying and Selling Activity at Beam Therapeutics

This chart shows John M Evans's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $24.28
Low: $24.01
High: $25.47

50 Day Range

MA: $32.80
Low: $23.90
High: $45.07

2 Week Range

Now: $24.28
Low: $16.95
High: $49.50


488,766 shs

Average Volume

1,441,748 shs

Market Capitalization

$1.98 billion

P/E Ratio


Dividend Yield